What’s Going On with MMEDF?
MindMed (MMEDF), a psychedelic medicine biotech company, announced its shares were approved for listing on NASDAQ, with trading commencing on April 27 under the symbol “MNMD.” The company will maintain it’s Neo Exchange Inc. listing and continue to trade on OTCQB under the symbol “MMEDF” until the NASDAQ trading begins.
What Does It Mean for MindMed?
The NASDAQ listing will “increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base,” said J.R. Rahn, CEO and co-founder of MindMed.
“I would like to thank our employees, management, directors and our many collaborators for their hard work in making MindMed a member of the Nasdaq exchange, an important step that will help facilitate our mission to discover, develop and deploy psychedelic inspired medicines and therapies to address addiction and mental illness,” Rahn added.
MMEDF has a Short-Term Technical Rank of 88. Find out what this means to you and get the rest of the rankings on MMEDF!
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
